|
楼主 |
发表于 2008-11-20 11:04:14
|
显示全部楼层
126-6-第六节 他克莫司应用中的注意事项
大剂量FK506治疗时可引起心室或室间隔肥大,少数病例可发生心肌损害,降低剂量或停止给药可逆转。用药期间建议定期检查心电图、超声心动图等,尤其是合并心脏疾病、使用激素、高血压、肝肾功能不全,或水钠储留感染的患者。如果出现异常,应该考虑减量或者停药。
# F; D8 [" `" B, o' \
- P4 X9 b+ n& r6 Y 用药期间应避免联合应用其他强效的免疫抑制剂,包括抗淋巴血清治疗。有报告在2岁以下EB病毒感染的儿童中,有增加淋巴组织异常增生的危险。因此,在用药前,最好进行EB病毒检查,并在治疗期间小心监测。
0 M, u* ~) M1 h) X( k1 i
4 B/ i1 R1 @8 N% W5 g$ g) z FK506可能引起高钾血症,所以不适用于高钾患者,肾功能异常者也应慎用,同时,用药期间应避免摄取高钾食物或使用保钾型利尿剂。 ) f8 ]- {% S" U& n7 e
0 d6 ?& i: t1 Q# A FK506浓缩输注液中含有聚乙烯氢化蓖麻油,曾报告会产生过敏反应,包括有皮肤潮红、呼吸困难、哮喘、血压下降及心动过速等。动物试验提示,若注射时减慢速度,或事先给予抗组胺药可降低过敏反应的发生率。 + ~0 @, {6 j! h1 @2 C
0 f) M4 q! j- _
应用FK506期间,应对以下方面进行监测:血常规、血肌醉、尿素氮、肝功能、电解质、血糖、凝血指标、血压、心电图和眼科检查。如有异常,必需调整剂量,甚至停药观察。 $ k# D( C+ D9 S C/ C
( 穆 荣 )$ N5 F& Y$ X- w0 L9 H
参考文献:5 y) p3 H. _- C0 ^+ c8 l
% q c' T/ G3 J* y: n. G8 t Assmann T, Homey B, Ruzicka T. Topical tacrolimus for thetreatment of inflammatory skin口iseases. Expert Opin Pharma-cother,2001.2(7) :1167一1175 0 H G8 m& U$ n# i$ M6 u( H
8 L- _, g( x, Y
Bekersky I, Lilja H, Lawrence I. Tacrolimus pharmacology and nonclinical studies: from FK506 to protopic. Semin CutanMed Surg,2001.20(4):226一232 ' e$ v& G& h5 l: p) C9 T" F+ N
! U2 G1 J6 d( r9 i9 u- E h4 T1 J Fam AG. Recent advances in the management of adultmyositis. Expert Opin Investig Drugs,2001.10(7):1265一1277 4 b( A" o5 T! S8 T
: g3 s9 i/ R6 {, m Gremillion RB, POsever JO, Manek N, et al. Tacrolimus inthe treatment of severe, refractory rheumatoid arthritis: initial ex-perience in 12 patients. j Rheumato1,1999.26(11) :2332一2336. - l" {1 q( R+ n, h+ o
5 B5 A' F3 e6 \, S; z Heneghan MA, McFarlane IG. Current and novel immuno-suppressive therapy for autoimmune hepatitis. Hepatology,2002.35(1):7一13 . N+ s, k& z5 ^) W4 I5 E8 X
& [7 I. a' }+ y) q2 V: g Hunt SA. New immunosuppressive agents in clinical use: my-cophenolate mofetil and tacrolimus. Cardiol Rev, 2000. 8 (3):180一184
' P8 ?" h f* ^1 v/ q: g7 v8 A' {' H4 [
Liu J, Farmer JD, Lane WS, et. al. Calcineurin is a commentarget of cyclophilin-cyclosporin A and FKBP-FK506 complex.Cell,1991. 66:807 - K6 T5 o# m/ ]9 i/ y" \
. L5 a; o9 M" U0 v% |/ ?( H% ?; B4 W
Morton SJ , Powell RJ. Cyclosporin and tacrolimus: their usein a routine clinical setting for scleroderma. Rheumatology ( Oxi-ford),2000.39(8):865一869 8 _" M- {" l* h+ g* L- Q
' ~, w% g" T$ b( E; y. r
Oddis CV. Current approach to the treatment of polymyositisand dermatomyositis. Curr Opin Rheumatol,2000.12(6):492一497
7 q( R0 Q; M/ _+ U! D! v6 N9 e2 w) {4 X" _( b
Olyaei AJ,de Mattos AM, Bennett WM, et al. Nephrotoxici-ty of immunosuppressive drugs: new insight and preventive strate-gies. Curr Opin Crit Care, 2001.7(6) :384一389
, b8 C8 t& [, t" W p6 |- K( b$ u8 b& R) |4 V! J- G8 G2 ^" d
Schreiber SL,Grabtree GR. The mechanism of action of Cy-closprine A and FK-506. Immunol Today, 1992. 13:136
2 O: \/ S7 Q, p0 C- `4 t
. w* w- P5 v/ ]* q% `! s0 P& d& r Thomas-Golbanov C, Sridharan S. Novel therapies in vasculi-tis. Expert Opin Investig Drugs, 2001.10(7):1279一1289
0 s$ u+ x4 t- G& `! z9 ?
: q% D. a+ i- o2 x Wassim Y, Almawi and Ohannes K. Melemedjian. Clinicaland mechanistic differences between FK506(tacrolimus) and cy-closporin A. Nephrol Dial Transplant, 2000.15:1916一1918
2 P8 h$ C: @* s F
- ^ g: F& B9 H. D' p( }' p* u' k) n Wong SH. Therapeutic drug monitoring for immunosup-pressants.Clin Chim Acts, 2001313(1一2):241一253
; n9 c7 {( R) |& s6 t6 g* G; t9 @; E* |( C9 i- h8 b4 H: t( {
Yoshimasu T, Ohtani T, Sakamoto Y, et al. Topicaltacrolimus therapy for facial erythematous lesions of cutaneous lu-pus erythematosus and dermatomyositis. Eur J Dermatol, 2002. 12(I):50一52 |
|